--- title: "InventisBio Co., Limited (688382.SH)" type: "Symbol" locale: "en" url: "https://longbridge.com/en/quote/688382.SH.md" symbol: "688382.SH" name: "InventisBio Co., Limited" industry: "Biotechnology" datetime: "2026-05-20T05:56:15.934Z" locales: - [en](https://longbridge.com/en/quote/688382.SH.md) - [zh-CN](https://longbridge.com/zh-CN/quote/688382.SH.md) - [zh-HK](https://longbridge.com/zh-HK/quote/688382.SH.md) --- # InventisBio Co., Limited (688382.SH) ## Company Overview InventisBio Co., Limited, a clinical stage biotech company, engages in the discovery and development of therapeutics for cancer and metabolic diseases in China. The company’s drug candidates for the oncology therapeutic area include BPI-D0316, which is in Phase III clinical trial for the non-small cell lung cancer (NSCLS) indications; Taragarestrant, which is in Phase III clinical trial for the treatment of estrogen receptor positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer; and Gesorexel, which in Phase II clinical trial to treat various cancers, such as non-small cell lung cancer and colorectal cancer with KRASG12C mutations. Its drug candidates for the metabolic therapeutic area is D-0120, a Phase II clinical trial product for hyperuricemia and gout indications; and D-2570, a oral selective inhibitor for the treatment of autoimmune diseases such as psoriasis. In addition, the company offers preclinical products, including YF 087 for MSI high cancers, and YF550 for chromosome instability cancers. | Item | Detail | |------|--------| | Industry | Biotechnology | | Exchange | CN Market | | Website | [www.inventisbio.com](https://www.inventisbio.com) | ## Key Drivers > *AI-analyzed key factors driving this stock's performance* ## Longbridge Financial Score™: D > *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge* > Updated: 2026-05-20T04:30:09.000Z **Overall: D (0.66)** **Industry**: Biotechnology | Metric | Value | |--------|-------| | Industry Ranking | 69 / 81 | | Industry Median | C | | Industry Average | C | - **Style**: Blend - Stocks in which the company has both growth and mature businesses. - **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns. **Multi Score**: D #### Style Score Score: | Indicator | Value | Rating | |-----------|-------|--------| | Revenue YoY | -57.45% | | | Net Profit YoY | -41.58% | | | P/B Ratio | 7.83 | | | Dividend Ratio | 0.00% | | #### Size Score Score: | Indicator | Value | Rating | |-----------|-------|--------| | Market Cap | 11726594581.63 | | | Revenue | 71770486.90 | | #### Multi Score Score: D | Indicator | Value | Rating | |-----------|-------|--------| | ROE | -18.60% | E | | Profit Margin | -423.95% | E | | Gross Margin | 96.17% | A | | Revenue YoY | -57.45% | E | | Net Profit YoY | -41.58% | D | | Total Assets YoY | -14.53% | E | | Net Assets YoY | -15.50% | E | | Cash Flow Margin | 77.72% | C | | OCF YoY | -57.45% | E | | Turnover | 0.04 | E | | Gearing Ratio | 6.58% | A | ```chart-data:radar { "title": "Longbridge Financial Score - InventisBio Co., Limited", "chart_type": "radar", "dimensions": [ { "name": "Style Score", "grade": "", "indicators": [ { "name": "Revenue YoY", "value": "-57.45%", "rating": "" }, { "name": "Net Profit YoY", "value": "-41.58%", "rating": "" }, { "name": "P/B Ratio", "value": "7.83", "rating": "" }, { "name": "Dividend Ratio", "value": "0.00%", "rating": "" } ] }, { "name": "Size Score", "grade": "", "indicators": [ { "name": "Market Cap", "value": "11726594581.63", "rating": "" }, { "name": "Revenue", "value": "71770486.90", "rating": "" } ] }, { "name": "Multi Score", "grade": "D", "indicators": [ { "name": "ROE", "value": "-18.60%", "rating": "E" }, { "name": "Profit Margin", "value": "-423.95%", "rating": "E" }, { "name": "Gross Margin", "value": "96.17%", "rating": "A" }, { "name": "Revenue YoY", "value": "-57.45%", "rating": "E" }, { "name": "Net Profit YoY", "value": "-41.58%", "rating": "D" }, { "name": "Total Assets YoY", "value": "-14.53%", "rating": "E" }, { "name": "Net Assets YoY", "value": "-15.50%", "rating": "E" }, { "name": "Cash Flow Margin", "value": "77.72%", "rating": "C" }, { "name": "OCF YoY", "value": "-57.45%", "rating": "E" }, { "name": "Turnover", "value": "0.04", "rating": "E" }, { "name": "Gearing Ratio", "value": "6.58%", "rating": "A" } ] } ] } ``` ## Valuation Analysis | Metric | Current | Industry Ranking | High | Median | Low | |--------|---------|-----------------|------|--------|-----| | PE (TTM) | -38.54 | 65/81 | - | - | - | | PB | 7.83 | 65/81 | 11.41 | 9.75 | 7.97 | | PS (TTM) | 163.39 | 81/81 | 139.23 | 97.71 | 80.58 | | Dividend Yield | 0.00% | - | - | - | - | ## Peer Comparison | Rank | Name | Profit | Growth | Operation | Security | Cash | Rating | | --- | --- | --- | --- | --- | --- | --- | --- | | 01 | Sunshine Guojian Pharmaceutical (688336.SH) | A | A | B | A | B | A | | 02 | AMOYTOP (688278.SH) | A | A | A | A | B | A | | 03 | BeOne Medicines (688235.SH) | B | A | B | C | A | B | | 04 | RemeGen (688331.SH) | A | A | C | C | B | B | | 05 | InnoCare Pharma (688428.SH) | B | A | D | B | B | B | ## Institutional View ### Analyst Rating Distribution > As of 2026-04-29T16:00:00.000Z Total Analysts: **3** | Rating | Count | Percentage | |--------|-------|-----------| | Buy | 2 | 67% | | Overweight | 1 | 33% | ### Target Price Forecast | Metric | Price | |--------|-------| | Current Price | 19.94 | | Highest Target | 32.55 | | Lowest Target | 32.55 | ## References - [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/688382.SH/overview.md) - [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/688382.SH/norm.md) - [Related News](https://longbridge.com/en/quote/688382.SH/news.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**